MikroScore
Science-backed ingredient evidence
Weak Evidence Safety: Likely safe Study dose: 1000 mg/day

TMG (Trimethylglycin)

Also known as: Trimethylglycin, Betaine, TMG

Summary Weak Evidence

TMG provides methyl groups and correlates with lower homocysteine. Biochemically plausible but as a healthy aging supplement, it's more niche than essential.

EU Health Claims: No approved claims

For betaine in the EU, only narrow, specific claims regarding homocysteine metabolism under defined conditions are permitted. Broad healthy aging, performance, or liver claims lack regulatory approval.

AI Summary

Quick verdict

TMG provides methyl groups and correlates with lower homocysteine. Biochemically plausible but as a healthy aging supplement, it's more niche than essential.

What the evidence supports

TMG as a methyl-group donor is biochemically well understood and correlates with lower homocysteine. Whether this translates into meaningful health or healthy aging benefits in healthy adults remains much less clear.

What is NOT supported

Clinical human trials are absent or very weak. Long-term safety in humans is largely unexplored.

EU/EFSA status

Not approved. For betaine in the EU, only narrow, specific claims regarding homocysteine metabolism under defin…

Safety

Likely safe

This AI summary is generated from the structured data on this page.

What is TMG?

TMG, or trimethylglycin (also known as betaine), is an organic compound that exists naturally in many plants and animals, including beets, spinach, and cereals. It functions primarily as a methyl-group donor in metabolic pathways and as an osmolyte—a molecule that helps regulate cellular water balance and stress responses. In supplement form, TMG is typically derived from sugar beets and used to modulate homocysteine metabolism, support cellular methylation, and potentially enhance athletic performance.

Mechanisms: How Does TMG Work?

TMG operates through two main metabolic roles:

1. Methylation pathway

TMG donates methyl groups (CH₃) to homocysteine, converting it to methionine via the enzyme betaine:homocysteine methyltransferase (BHMT). This is a well-established biochemical pathway confirmed in vitro and in animal models. Methylation is central to DNA synthesis, gene expression, neurotransmitter production, and immune function, which is why researchers hypothesize TMG could support these processes.

2. Osmolytic function

As an osmolyte, TMG accumulates in cells under stress (heat, dehydration, hyperosmolarity) and helps maintain cell volume and protein stability. This mechanism is robust in cellular and animal models, which is why some sports supplement formulators include TMG to support muscle endurance and hydration status.

What the Evidence Actually Shows

Homocysteine reduction (moderate evidence)

The most consistent finding is that TMG supplementation lowers plasma homocysteine in healthy adults. Key studies:

  • Olthof et al. (2003): In a double-blind, crossover trial with 60 healthy participants, 6 g/day TMG for 12 weeks reduced fasting homocysteine by approximately 10–13% compared to placebo. Effect size was modest but reproducible across multiple dose arms.

  • Craig (2004) review: Concluded TMG reliably reduces homocysteine in vitro and in animal models, with human data showing 10–20% reductions depending on baseline homocysteine and dose.

Importantly, lower homocysteine does not automatically mean better health outcomes. Homocysteine is an independent cardiovascular risk marker in observational studies, but clinical trials of homocysteine-lowering interventions (including B-vitamins and folate) have largely failed to reduce cardiovascular events (VISP trial, HOPE-2 substudy, NORVIT). This is a critical gap: TMG lowers the biomarker, but we lack evidence that this translates to disease prevention.

Athletic performance (weak-to-mixed evidence)

TMG is sometimes marketed to athletes as an ergogenic aid. The proposed mechanism: osmolytic effect → better muscle hydration → improved endurance and recovery. However:

  • Most studies are small, short-term, and use low doses (2–3 g/day for 7–14 days).
  • Results are inconsistent: some show marginal improvements in time-to-fatigue or power output; others show no effect.
  • No large, well-powered RCTs exist comparing TMG to placebo in trained athletes over ≥8 weeks.
  • Practical significance of any effects (if real) is unclear—typically in the 2–5% range, if detected at all.

Liver function (limited evidence)

TMG is claimed to support liver health and methylation-dependent detoxification. However:

  • Evidence is primarily mechanistic (TMG is a methyl donor, the liver uses methylation).
  • Human trials specifically testing TMG on liver function, fatty liver, or transaminase levels are sparse.
  • One small study in animals with induced liver damage showed some protective effect, but clinical relevance is unclear.

Cardiovascular outcomes (no evidence)

Despite reducing homocysteine, no RCTs have shown that TMG prevents cardiovascular disease, stroke, or mortality in humans. This is the crucial missing piece: biochemical plausibility ≠ clinical benefit.

Regulatory Status (EU/EFSA)

In the European Union, betaine/TMG has no approved health claims for general population use. EFSA has only permitted narrow, conditional claims for homocysteine reduction under specific, limited conditions. Broad claims about “healthy aging,” cardiovascular protection, or general wellness are not permitted. This reflects the gap between biochemical mechanism and proven clinical outcomes.

Safety Profile

TMG is generally well-tolerated:

  • No serious adverse events reported in published trials at doses up to 15 g/day.
  • Mild GI upset (nausea, bloating) occasionally reported at high doses.
  • No significant drug interactions documented.
  • Classified as “likely safe” by natural product safety databases.

However, long-term safety data (beyond 12 weeks) is limited, and effects in populations with kidney disease or specific genetic polymorphisms in folate/B₁₂ metabolism remain understudied.

The Bottom Line

TMG is a biochemically rational compound with clear mechanistic support for reducing homocysteine and modulating methylation. However, the evidence-to-benefit pipeline breaks down at clinical outcomes:

  • Evidence for mechanism: Strong
  • Evidence for biomarker reduction: Moderate
  • Evidence for disease prevention or health improvements in healthy adults: Weak-to-absent

For most people, optimizing homocysteine through diet (folate, B₆, B₁₂) and lifestyle is better supported than supplemental TMG. TMG might be considered in specific contexts—e.g., for athletes exploring osmolytic strategies, or in patients with genetic homocysteine metabolism disorders—but it is not a cornerstone longevity supplement and should not be prioritized over proven interventions like exercise, sleep, and metabolic health.

Key Studies

Betaine in human nutrition

Craig SA (2004)

Review: TMG is metabolically relevant, particularly as a methyl-group donor and osmolyte. Clinical applications sometimes outpace the evidence base.

PubMed PMID 15321791

Plasma lipids and betaine are related in an acute coronary syndrome cohort

Lever M et al. (2011)

Homocysteine decreases, but hard clinical endpoints remain unclear.

PubMed PMID 21747945
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.